SRR12202494
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- ALLOGRAFT_REJECTION+0.550
- ANGIOGENESIS+0.550
- TNFA_SIGNALING_VIA_NFKB+0.530
- PANCREAS_BETA_CELLS+0.510
- INFLAMMATORY_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.490
- HEDGEHOG_SIGNALING+0.470
- KRAS_SIGNALING_UP+0.430
- MYOGENESIS+0.400
Top 10 suppressed
- DNA_REPAIR-0.500
- E2F_TARGETS-0.450
- MYC_TARGETS_V2-0.430
- OXIDATIVE_PHOSPHORYLATION-0.410
- PROTEIN_SECRETION-0.380
- MYC_TARGETS_V1-0.360
- G2M_CHECKPOINT-0.340
- PEROXISOME-0.220
- ADIPOGENESIS-0.210
- UNFOLDED_PROTEIN_RESPONSE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-AAME-01A-12R-A42T-07 | — | — | 0.940 |
| 2 | GSM5359443 | — | — | 0.932 |
| 3 | TCGA-38-7271-01A-11R-2039-07 | — | cohortMD2 | 0.931 |
| 4 | TCGA-K4-A83P-01A-11R-A352-07 | — | — | 0.925 |
| 5 | BS_G1Y281HX | Neuroblastoma | — | 0.916 |
| 6 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.915 |
| 7 | DRR168569 | — | — | 0.911 |
| 8 | R52 | — | — | 0.911 |
| 9 | SRR604456 | GTEX | — | 0.911 |
| 10 | TCGA-4Z-AA7N-01A-11R-A39I-07 | — | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.430 | Inavolisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |